Assessment of adverse reaction rates to a newly approved MRI contrast agent: Review of 23,553 administrations of gadobenate dimeglumine

American Journal of Roentgenology

Volumn 191, Issue 6, 2008, Pages

  Bleicher, Andrew G ^a   Kanal, Emanuel ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Contrast reactions; Gadolinium based MR contrast agents; MRI

Indexed keywords

GADOBENATE DIMEGLUMINE;

ANGIONEUROTIC EDEMA; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY SYSTEM; HUMAN; HYPERTENSIVE CRISIS; MAGNETIC RESONANCE ANGIOGRAPHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY HALLUCINATION; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN TINGLING; SNEEZING; THORAX PAIN; URTICARIA; VOMITING;

CONTRAST MEDIA; DYSPNEA; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; NAUSEA; ORGANOMETALLIC COMPOUNDS; PENNSYLVANIA; RISK ASSESSMENT; RISK FACTORS; URTICARIA; VOMITING;

EID: 57149102552     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.3951     Document Type: Review

References (28)

1. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003; 14:426-435
2. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22:3174-3178
3. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157
4. Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007; 17:70-76
5. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 2007; 48:593-596
6. Guideline for industry. Clinical safety data management: definitions and standards for expedited reporting, 1995. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research Website. www.fda.gov/cder/guidance/iche2a.pdf. Accessed August 28, 2008
7. ICH harmonised tripartite guideline draft. Post-approval safety data management: definitions and standards for expedited reporting, 2003. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research Website. www.fda.gov/cber/gdlns/ichexrep.htm. Accessed August, 2008
8. Guidance for industry. Adverse reactions section of labeling for human prescription drug and biological products: content and format, 2006. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research Website. www.fda.gov/Cber/gdlns/cfadvers.htm. Accessed August 28, 2008
9. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584-591
10. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391-397
11. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006; 41:491-499 [Erratum in Invest Radiol 2006; 41:667]
12. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR 2007; 188:1447-1474
13. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; 242:647-649
14. Shellock FG, Parker JR, Venetianer C, Pirovano G, Spinazzi A. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol 2006; 41:500-509
15. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006; 24:1378-1385
16. Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. Pediatr Radiol 2005; 35:501-510
17. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology 2005; 237:45-56
18. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006; 240:389-400
19. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol 2006; 41:244-248
20. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007; 106:557-566
21. Marin D, Iannaccone R, Laghi A, et al. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2007; 25:775-782
22. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003; 14:426-435
23. Bailar JC 3rd. The promise and problems of meta-analysis. N Engl J Med 1997; 337:559-561
24. LeLorier J, Gregoire G. Comparing results from meta-analyses vs large trials. JAMA 1998; 280:518-519
25. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536-542
26. Kirchin MA, Pirovano G, Venetianer C, Spinazzi A. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 2001; 14:281-294
27. Hieronim DE, Kanal E, Swanson DP. Dosage of gadoteridol and adverse reactions relative to gado pentetate. Am J Health Syst Pharm 1995; 52:2556-2559
28. Kanal E, Applegate GR, Gillen CP. Review of adverse reactions, including anaphylaxis, in 4260 intravenous bolus injections. Radiology 1990; 159:177